文献速递腹部技术与安全US

超声造影用于局灶性肝脏病变定性:一项综合Meta分析

Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.
PubMed 文献 · Eur Radiol · 2017-11-30

该Meta分析系统检索Cochrane Library、PubMed和Web of Science数据库,纳入57项使用超声造影(CEUS)定性局灶性肝脏病变(FLLs)的研究并提取2×2表数据,采用QUADAS工具评价方法学质量。合并敏感度0.92(95%CI: 0.91-0.93),合并特异度0.87(95%CI: 0.86-0.88),诊断比值比104.20(95%CI: 70.42-154.16)。亚组分析显示第二代造影剂诊断准确性高于第一代Levovist(DOR: 118.27 vs. 62.78),Sonazoid在三种主要造影剂中诊断准确性最高(DOR: 118.82 vs. 62.78 vs. 227.39)。

要点

  • CEUS鉴别FLLs良恶性的合并敏感度0.92(95%CI: 0.91-0.93)、合并特异度0.87(95%CI: 0.86-0.88)。
  • 第二代造影剂诊断准确性高于第一代Levovist(DOR: 118.27 vs. 62.78)。
  • Sonazoid在SonoVue、Levovist和Sonazoid三种造影剂中诊断准确性最高(DOR: 118.82 vs. 62.78 vs. 227.39)。

核心结论

  • CEUS是分层评估FLLs恶性风险的准确工具,第二代造影剂尤其是Sonazoid可能大幅提高诊断性能。

研究设计与样本

  • Meta分析,系统检索Cochrane Library、PubMed和Web of Science数据库,纳入57项使用CEUS定性FLLs的研究,提取构建2×2列联表所需数据。

诊断标准与关键数值

  • CEUS鉴别FLLs良恶性的合并敏感度0.92(95%CI: 0.91-0.93)。
  • CEUS鉴别FLLs良恶性的合并特异度0.87(95%CI: 0.86-0.88)。
  • CEUS鉴别FLLs良恶性的诊断比值比104.20(95%CI: 70.42-154.16)。
  • 第二代造影剂DOR 118.27 vs. 第一代Levovist DOR 62.78。
  • Sonazoid DOR 227.39 vs. SonoVue DOR 118.82 vs. Levovist DOR 62.78。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This meta-analysis was performed to evaluate the accuracy of contrast-enhanced ultrasound (CEUS) in differentiating malignant from benign focal liver lesions (FLLs).

METHODS: Cochrane Library, PubMed and Web of Science databases were systematically searched and checked for studies using CEUS in characterization of FLLs. Data necessary to construct 2×2 contingency tables were extracted from included studies. The QUADAS tool was utilized to assess the methodologic quality of the studies. Meta-analysis included data pooling, subgroup analyses, meta-regression and investigation of publication bias was comprehensively performed.

RESULTS: Fifty-seven studies were included in this meta-analysis and the overall diagnostic accuracy in characterization of FLLs was as follows: pooled sensitivity, 0.92 (95%CI: 0.91-0.93); pooled specificity, 0.87 (95%CI: 0.86-0.88); diagnostic odds ratio, 104.20 (95%CI: 70.42-154.16). Subgroup analysis indicated higher diagnostic accuracy of the second-generation contrast agents (CAs) than the first-generation CA (Levovist; DOR: 118.27 vs. 62.78). Furthermore, Sonazoid demonstrated the highest diagnostic accuracy among three major CAs (SonoVue, Levovist and Sonazoid; DOR: 118.82 vs. 62.78 vs. 227.39). No potential publication bias was observed of the included studies.

CONCLUSION: CEUS is an accurate tool to stratify the risk of malignancy in FLLs. The second-generation CAs, especially Sonazoid may greatly improve diagnostic performance.

KEY POINTS: • CEUS shows excellent diagnostic accuracy in differentiating malignant from benign FLLs. • The second-generation CAs have higher diagnostic accuracy than first-generation CAs. • Sonazoid demonstrates the highest diagnostic accuracy among three major CAs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wu M, Li L, Wang J, et al. Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis. Eur Radiol. 2017. PMID: 29189932. doi:10.1007/s00330-017-5152-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。